COVID-19 vaccination in Hungary

Statement from the Chief Public Health Officer of Canada on July 22, 2021

Retrieved on: 
Thursday, July 22, 2021
Health, Articles, Health Canada, Medicine, National Advisory Committee on Immunization, COVID-19 vaccine, Public Health Agency of Canada, Vaccine, Vaccination, COVID-19 vaccination in Canada, COVID-19 vaccination in Hungary

OTTAWA, ON, July 22, 2021 /CNW/ -Today, Canada'sNational Advisory Committee on Immunization (NACI) hasreleased updated guidance on the use of COVID-19 vaccines.

Key Points: 
  • OTTAWA, ON, July 22, 2021 /CNW/ -Today, Canada'sNational Advisory Committee on Immunization (NACI) hasreleased updated guidance on the use of COVID-19 vaccines.
  • NACI's latest guidance, continues to recommend that people who were previously infected with the SARS-CoV-2 virus may receive a full series of COVID-19 vaccines.
  • The Public Health Agency of Canada(PHAC) is also providing regular updates on COVID-19 vaccines administered , vaccination coverage and ongoing monitoring of vaccine safety across the country.
  • As public health restrictions are eased, some increase in cases, particularly among unvaccinated populations, is not unexpected.

Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, June 3, 2021
Clinical trials, COVID-19 vaccines, Vaccines, Drugs, Vaccination, VLA2001, Valneva SE, COVID-19 vaccine, Inactivated vaccine, COVID-19 vaccination in Norway, COVID-19 vaccination in Hungary

Over 4,000 volunteers in the United Kingdom have been randomized in the Phase 3 trial Cov-Compare (VLA2001-301), which compares Valnevas SARS-CoV-2 vaccine candidate, VLA2001, against AstraZenecas conditionally approved vaccine, Vaxzevria1.

Key Points: 
  • Over 4,000 volunteers in the United Kingdom have been randomized in the Phase 3 trial Cov-Compare (VLA2001-301), which compares Valnevas SARS-CoV-2 vaccine candidate, VLA2001, against AstraZenecas conditionally approved vaccine, Vaxzevria1.
  • Based on our Phase 1/2 clinical data and, assuming successful Phase 3 results, we believe that our inactivated vaccine can make a major contribution to the ongoing fight against the COVID-19 pandemic.
  • Valneva recently announced that it is participating in the worlds first COVID-19 vaccine booster trial in the UK2.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.